Introduction
============

Oral cancer is the sixth most common cancer worldwide, with a high prevalence in regions where individuals habitually smoke cigarettes and consume alcohol ([@b1-ol-08-01-0218]). In addition, the five-year relative survival rate of distant metastasis for oral cancer is \~30--40% ([@b2-ol-08-01-0218]). In the USA, \~41,380 individuals are diagnosed with oral cancer annually and \~7,890 individuals succumbed to the disease in 2012 ([@b3-ol-08-01-0218]).

MicroRNAs (miRNAs) are a family of endogenous, non-coding, 22--25 nt RNAs that regulate target mRNA. Accumulating evidence indicates that miRNAs are involved in important biological processes associated with apoptosis, proliferation, differentiation, angiogenesis and metastasis. Therefore, the deregulation of such processes may exhibit an effect on cancer initiation, progression and treatment outcome ([@b4-ol-08-01-0218],[@b5-ol-08-01-0218]).

It is hypothesized that miRNAs may serve as valuable tools in cancer diagnosis. Previous studies using miRNA microarray analysis have identified statistically unique profiles, which may discriminate cancer samples from healthy control samples ([@b6-ol-08-01-0218]). Siow *et al* ([@b7-ol-08-01-0218]) used an miRNA microarray to identify the differentially expressed miRNAs (DE-miRNAs) between oral squamous cell carcinoma and non-cancer cells, and miR-31 and miR-375 were found to significantly correlate with clinicopathological parameters.

The aim of the present study was to identify the miRNAs, which may be important in the progression of oral cancer and to analyze their involvement in this process. An independent sample t-test was used to analyze the raw data in order to obtain credible data of the DE-miRNAs. In addition, an interaction network was constructed using the Search Tools for the Retrieval of Interacting Genes (STRING) database and Cytoscape software. The results of the current study support the hypothesis that miRNA expression is deregulated in oral cancer patients compared with healthy individuals.

Materials and methods
=====================

Microarray analysis
-------------------

The miRNA expression profile of GSE28100 \[the Gene Expression Omnibus (GEO) accession number\] was downloaded from the GEO database, which was collected by Jung *et al* ([@b8-ol-08-01-0218]). The expression data of miRNAs was obtained using the GEO accession number, GSE28100, with the purpose of identifying aberrantly expressed miRNAs in oral squamous cell carcinomas. The expression profiles of miRNAs in 17 patients with oral cancer and three healthy control subjects were available.

Identification of DE-miRNAs
---------------------------

The raw data were transformed into identifiable expression data and the missing data was completed. Background corrections and quartile data normalization were performed with the robust multi-array average using the default parameters in the affy package. In addition, the data were analyzed using BRB-ArrayTools version 4.2 (National Cancer Institute; <http://linus.nci.nih.gov/BRB-ArrayTools.html>).

Predicting the target genes of DE-miRNAs
----------------------------------------

The miRecords database (<http://miRecords.umn.edu/miRecords>), which is a resource for animal miRNA-target interactions, was used to analyze the target genes of the DE-miRNAs. miRecords integrates the predicted targets of the following miRNA target prediction tools: DIANA-microT (<http://diana.csla-b.ece.ntua.gr/microT>), MicroInspector (<http://bioinfo.uni-plovdiv.bg/microinspector>), miRanda (<http://www.microrna.org/microrna/home.do>), MirTarget2 (<http://mirdb.org/miRDB>), miTarget™ (<http://cbit.snu.ac.kr/~miTarget>), NBmiRTar (<http://wotan.wistar.upenn.edu/NBmiRTar/login.php>), PicTar (<http://pictar.bio.nyu.edu>), PITA (<http://genie.weizmann.ac.il/index.html>), RNA22 (<http:/cbcsrv.watson.ibm.com/rna22.html>), RNAhybrid (<http://bibiserv.techfak.uni-bielefeld.de/rnahybrid>) and TargetScan (<http://www.targetscan.org>). The genes that were predicted by at least five of the 10 databases were selected as DE-miRNA targets for subsequent analysis to reduce the quantity of false-positive results.

Network analysis and functional annotation
------------------------------------------

The STRING database includes experimental and predicted interaction information and STRING version 9.1 comprises of \>1,100 completely sequenced organisms ([@b9-ol-08-01-0218]). To identify the interactive associations between the target genes and other genes, the target genes of DE-miRNAs were input into STRING. The Cytoscape software was used to visualize these associations and the mined modules.

The Database for Annotation, Visualization and Integrated Discovery (DAVID) includes a broad selection of functional annotation tools for understanding the biological significance of numerous genes. In the current study, DAVID was used to label the function of genes within the modules and the Gene Ontology (GO) terms with an adjusted P-value of \<0.05 and a count \>2 were selected.

Statistical analysis
--------------------

An independent sample t-test was used to identify the DE-miRNAs between the oral cancer patients and healthy control subjects, and P\<0.001 was considered to indicate a statistically significant difference.

Results
=======

Identification of DE-miRNAs
---------------------------

miRNA expression data was obtained using the accession number, GSE28100, and included 17 patients with oral cancers and three healthy control subjects. The miRNA expression data was analyzed by BRB-ArrayTools and 15 miRNAs exhibited significant differential expression (P\<0.001; [Table I](#tI-ol-08-01-0218){ref-type="table"}).

Target gene prediction
----------------------

Since miRNAs regulate the post-transcriptional regression of target genes, the putative target genes of DE-miRNAs were retrieved from miRecords, which selects the target genes that have been retrieved by at least five databases. Furthermore, these target genes were searched for using PubMed and a large list of target genes were confirmed to be associated with oral cancer ([Table II](#tII-ol-08-01-0218){ref-type="table"}). Among these genes, hsa-miR-15a had the greatest number of target genes associated with oral cancer.

Interaction network construction and module analysis
----------------------------------------------------

The target genes of 12 DE-miRNAs were input into the STRING database, which identified the significant interactions with a confidence score of \>0.9. In addition, a protein-protein interaction (PPI) network was constructed using Cytoscape software ([Fig. 1](#f1-ol-08-01-0218){ref-type="fig"}).

The PPI network reveals the molecular mechanisms of oral cancer, however, it contains numerous nodes and interactions, which makes it difficult to select the useful information. Therefore, the modules were mined in the PPI network to include insulin-like growth factor (IGF)2-receptor (R), cluster of differentiation 44, IGF2, IGF1-R and fibroblast growth factor (FGF)2. Functional analysis demonstrated that the genes in this module could be divided into 21 functional GO terms (the 10 most significant terms are shown in [Table III](#tIII-ol-08-01-0218){ref-type="table"}). Among these functional nodes, the most significant GO category was identified to be the FGF-R signaling pathway.

The target genes of FGF2 were identified to be associated with the GO categories of apoptosis, programmed cell death, cell migration, cell death and cell motility.

Discussion
==========

In the present study, 15 DE-miRNAs were identified to exhibit a regulatory function in the progression of oral cancer. As a result of retrieving the target genes of the DE-miRNAs from miRecords, the target genes of 12 DE-miRNAs were found to be associated with oral cancer. Through PPI network construction and module analysis, an FGF2 module was formed and was identified to be significant in the progression of oral cancer. Furthermore, functional analysis showed that the module was significantly associated with the FGF-R signaling pathway.

The expression of 12 DE-miRNAs, including hsa-miR-15a, was identified as a possible biomarker to monitor oral cancer progression and early diagnosis. In addition, hsa-miR-15a was found to be downregulated in certain hematological tumors and is considered to regulate cancer-associated genes that influence apoptosis, the cell cycle, proliferation and survival ([@b10-ol-08-01-0218],[@b11-ol-08-01-0218]). In addition, hsa-miR-15a is frequently downregulated in chronic lymphocytic leukemia, prostate cancer and non-small cell lung cancer ([@b12-ol-08-01-0218]--[@b14-ol-08-01-0218]), and the inhibition of hsa-miR-15a significantly increases the secreted matrix metalloproteinase-9 expression in neuroblastoma ([@b15-ol-08-01-0218]). However, Ricieri *et al* ([@b16-ol-08-01-0218]) identified that hsa-miR-15a expression levels were upregulated in the majority of oral cancers samples. The results of the current study using the accession number, GSE28100 revealed a 3.58-fold change in hsa-miR-15a expression, compared with that of the healthy control subjects, which indicated that hsa-miR-15a is involved in the progression of oral cancer.

In addition, FGF2 formed a module in the PPI network that was constructed based on oral cancer samples, which indicated that FGF2 has an important function in the progression of oral cancer. FGF2 is an 18-kDa non-glycosylated polypeptide consisting of 146 amino acids ([@b17-ol-08-01-0218]), which mediates various cellular events, including migration, angiogenesis, motility, proliferation and differentiation ([@b18-ol-08-01-0218],[@b19-ol-08-01-0218]).

In addition, FGF2 promotes tumor progression and previous studies indicate that the upregulation of FGF2 is important in prostate carcinogenesis and malignant progression ([@b20-ol-08-01-0218]). FGF2 is one of the most well-studied factors involved in angiogenesis ([@b21-ol-08-01-0218]). Lau *et al* ([@b22-ol-08-01-0218]) identified that the expression of FGF2 decreases E-cadherin levels by upregulating its transcriptional repressors, Slug and ZEB1, in human ovarian cancer cells.

The FGF-R, a sub-family of the superfamily of receptor tyrosine kinases, may regulate human development and metabolism. Previous studies have shown that FGF-R may be important in carcinogenesis ([@b23-ol-08-01-0218],[@b24-ol-08-01-0218]). Furthermore, studies have indicated that FGF-R1 is amplified in 20% of squamous non-small cell lung cancers ([@b25-ol-08-01-0218]) and mutations of FGF-R2 have been described in 12% of endometrial carcinomas ([@b26-ol-08-01-0218]). Furthermore, \~10% of gastric cancer cases exhibit FGF-R2 amplification and mutations ([@b27-ol-08-01-0218]).

In conclusion, the current study identified 15 DE-miRNAs, which may be important in the progression of oral cancer and hsa-miR-15a demonstrated the greatest quantity of target genes. In addition, FGF2 expression was identified to be significantly associated with the presentation of oral cancer. However, further investigation regarding the function of FGF2 is required.

![(A) PPI network construction. (B) The module identified from the PPI network. PPI, protein-protein interaction; PLAUR, plasminogen activator urokinase receptor; GGA, golgi-associated, γ adaptin ear containing, ARF binding protein; PLIN3, perilipin 3; IGF2R, insulin-like growth factor 2 receptor; GZMB, granzyme B; PACS1, phosphofurin acidic cluster sorting protein 1; IGF2BP, insulin-like growth factor 2 mRNA binding protein; IGF2, insulin-like growth factor 2; NF2, neurofibromin 2; HYAL2, hyaluronoglucosaminidase 2; HMMR, hyaluronan-mediated motility receptor; IGF1R, insulin-like growth factor 1 receptor; FGF2, fibroblast growth factor 2; FGFR, fibroblast growth factor receptor; PDGFRA, platelet-derived growth factor receptor, α polypeptide.](OL-08-01-0218-g00){#f1-ol-08-01-0218}

###### 

Differentially expressed miRNAs obtained using Gene Expression Omnibus accession number, GSE28100.

  n    miRNA             Fold change   P-value
  ---- ----------------- ------------- -----------
  1    hsa-miR-424       10.31         0.0000650
  2    hsa-miR-21        6.34          0.0002210
  3    hsa-miR-15b       7.81          0.0006760
  4    hsa-miR-923       0.21          0.0001064
  5    hsa-miR-146b-5p   5.54          0.0001082
  6    hsa-miR-331-3p    2.92          0.0001400
  7    hsa-miR-15a       3.58          0.0001929
  8    hsa-miR-26b       5.99          0.0003248
  9    hsa-miR-455-3p    5.18          0.0003526
  10   hsa-let-7f        6.49          0.0003598
  11   hsa-miR-27a       2.83          0.0005683
  12   hsa-miR-96        5.08          0.0006193
  13   hsa-miR-590-5p    3.00          0.0007849
  14   hsa-miR-28-5p     4.68          0.0008894
  15   hsa-let-7a        4.16          0.0009845

P\<0.001.

###### 

Target genes of differentially expressed miRNA.

  n    hsa-let-7a   hsa-let-7f   hsa-miR-15a   hsa-miR-15b   hsa-miR-21   hsa-miR-26b   hsa-miR-27a   hsa-miR-28-5p   hsa-miR-96   hsa-miR-146b-5p   hsa-miR-424   hsa-miR-590-5p
  ---- ------------ ------------ ------------- ------------- ------------ ------------- ------------- --------------- ------------ ----------------- ------------- ----------------
  1    ABCC5        ABCC5        ABCC5         ABCC5         SMAD7        APC           BMI1          HOXA1           CAV1         SMAD4             ABCC5         PLAG1
  2    ADRB2        ADRB2        ADRB2         ADRB2         CDC25A       ATM           CD28                          HOXA5                          ADRB2         SOX2
  3    CASP3        CASP3                      BCL2          PDCD4        CDK6          CD44                          KRAS                           BDNF          STAT3
  4    CCR7         CCR7         BDNF          BDNF          PDCD4        GSK3B         CYP1B1                        MTMR3                          CD28          WWP1
  5    CDC25A       CDC25A       CCND1         CCND1         PLAG1        HMGA2         EGFR                          PAK1                           CDC25A        
  6    COL1A1       COL1A1       CD28          CD28          SOX2         HOXA5         HOXA10                        RAC1                           CYP26B1       
  7    ERCC6        ERCC6        CDC25A        CDC25A        STAT3        HOXA9         ING5                          SMAD7                          FGF2          
  8    FASLG        HMGA2        CYP26B1       CYP26B1       STAT3        MAP2          KRAS                          ZIC2                           FGFR1         
  9    HMGA2        HOXA1        FGF2          FGF2          STAT3        PIM1          MSI1                                                         HOXA10        
  10   HOXA1        HOXA9        FGFR1         FGFR1         WWP1         PTEN          PLAG1                                                        MYB           
  11   HOXA9        IGF1R        HMGA2         HOXA10                     SENP5         SFRP1                                                        PLAG1         
  12   IGF1R        IGF2BP3      HOXA10        MYB                        SMAD4                                                                      SMAD3         
  13   IGF2BP3      IKBKE        IGF2R         PDCD4                                                                                                 SMAD7         
  14   IKBKE        IL10         MYB           PIM1                                                                                                  TGFBR3        
  15   IL10         SENP5        PDCD4         PLAG1                                                                                                 WWP1          
  16   KRAS                      PIM1          SMAD3                                                                                                               
  17   PAK1                      PLAG1         SMAD7                                                                                                               
  18   SENP5                     SMAD3         TGFBR3                                                                                                              
  19                             SMAD7         WWP1                                                                                                                
  20                             TGFBR3                                                                                                                            
  21                             WWP1                                                                                                                              

ABCC5, ATP-binding cassette, sub-family C; SMAD, SMAD family member 4; APC, adenomatosis polyposis coli; BMI1, BMI1 polycomb ring finger oncogene; HOXA, homeobox A cluster; CAV1, caveolin 1; PLAG1, pleiomorphic adenoma gene 1; ADRB2, adrenoceptor β2; CDC25A, cell division cycle 25A; ATM, ataxia telangiectasia mutated; SOX2, SRY (sex determining region Y)-box 2; CASP3, caspase 3, apoptosis-related cysteine peptidase; BCL2, B-cell lymphoma 2; PDCD4, programmed cell death 4; CDK6, cyclin-dependent kinase 6; KRAS, Kirsten rat sarcoma viral oncogene homolog; BDNF, brain-derived neurotrophic factor; STAT3, signal transducer and activator of transcription 3; CCR7, chemokine receptor 7; GSK3B, glycogen synthase kinase 3β; CYP1B1, cytochrome P450, family 1, subfamily B, polypeptide 1; MTMR3, myotubularin related protein 3; WWP1, WW domain containing E3 ubiquitin protein ligase 1; CDC25A, cell division cycle 25A; CCND1, cyclin D1; PLAG1, pleiomorphic adenoma gene 1; HMGA2, high mobility group AT-hook 2; EGFR, epidermal growth factor receptor; PAK1, p21 protein (Cdc42/Rac)-activated kinase 1; COL1A1, collagen, type I, α1; RAC1, ras-related C3 botulinum toxin substrate 1; CYP26B1, cytochrome P450, family 26, subfamily B, polypeptide 1; ERCC6, excision repair cross-complementation group 6; ING5, inhibitor of growth family, member 5; FGF2, fibroblast growth factor 2; FASLG, Fas ligand (TNF superfamily, member 6); MAP2, microtubule associated protein 2; ZIC2, Zic family member 2; FGFR1, fibroblast growth factor receptor 1; PIM1, pim-1 oncogene; MSI1, musashi RNA-binding protein 1; PTEN, phosphatase and tensin homolog; MYB, v-myb avian myeloblastosis viral oncogene homolog; IGF1R, insulin-like growth factor 1 receptor; SENP5, sentrin specific peptidase 5; SFRP1, secreted frizzled-related protein 1; IGF2BP3, insulin-like growth factor 2 mRNA binding protein 3; IKBKE, inhibitor of κ light polypeptide gene enhancer in B-cells, kinase epsilon; IGF2R, insulin-like growth factor 2 receptor; IL10, interleukin 10; TGFBR3, transforming growth factor, β receptor III.

###### 

Gene Ontology analysis of the 10 most significant target genes (False discovery rate, P\<0.05).

  n    Description                                                        P-value    Genes in test set
  ---- ------------------------------------------------------------------ ---------- -----------------------------------------------------
  1    Fibroblast growth factor receptor signaling pathway                0.000004   CEP5, FGF2, FGFR3 and FGFR4
  2    Transmembrane receptor protein tyrosine kinase signaling pathway   0.000087   CEP57, FGF2, FGFR3, FGFR4 and IGF1R
  3    Enzyme-linked receptor protein signaling pathway                   0.000440   CEP57, FGF2, FGFR3, FGFR4 and IGF1R
  4    Phosphate metabolic process                                        0.003100   FGFR2, FGF2, FGFR2, FGF4, IGF1R, SDC3
  5    Phosphorus metabolic process                                       0.003100   FGFR2, FGF2, FGFR2, FGF4, IGF1R, SDC3
  6    Phosphorylation                                                    0.009800   FGF2, FGFR3, FGFR4, IGF1R
  7    Positive regulation of cell proliferation                          0.009800   FGF2, FGFR3, FGFR4, IGF1R
  8    Cell surface receptor-linked signal transduction                   0.011000   CEP57, IGF2BP3, FGF2, FGFR3, FGFR4, IGF1R and PLAUR
  9    Wound healing                                                      0.018000   CD44, FGF2 and FN1
  10   Response to wounding                                               0.019000   CD44, IGF2BP3, FGF2 and FN1

CEP, caenorhabditis elegans; FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; IGF1R, insulin-like growth factor 1 receptor; SDC3, syndecan-3; IGF2BP3, insulin-like growth factor 2 mRNA binding protein 3; PLAUR, plasminogen activator urokinase receptor; FN1, fibronectin 1.
